Published in Nat Med on July 01, 2013
Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV | NCT02690103
Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. PLoS Pathog (2014) 2.13
Immune responses to HCV and other hepatitis viruses. Immunity (2014) 1.52
The inhibitory effects of anacardic acid on hepatitis C virus life cycle. PLoS One (2015) 1.40
Emerging therapies for hepatitis C. Gut Liver (2014) 1.07
Deep sequencing: becoming a critical tool in clinical virology. J Clin Virol (2014) 1.07
Surveying the global virome: identification and characterization of HCV-related animal hepaciviruses. Antiviral Res (2014) 1.06
Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc Natl Acad Sci U S A (2015) 1.03
Will there be a vaccine to prevent HCV infection? Semin Liver Dis (2014) 1.02
miR-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation. Cell Host Microbe (2015) 1.01
A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. PLoS Pathog (2014) 0.99
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol (2013) 0.96
Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog (2014) 0.96
Functionally conserved architecture of hepatitis C virus RNA genomes. Proc Natl Acad Sci U S A (2015) 0.96
Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection. Antimicrob Agents Chemother (2014) 0.94
Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep (2015) 0.94
Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J Gastroenterol (2014) 0.94
Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94
Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression. J Virol (2014) 0.93
Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. Hepatology (2015) 0.93
Unfolded protein response in hepatitis C virus infection. Front Microbiol (2014) 0.92
Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. Viruses (2015) 0.92
Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. Nature (2016) 0.92
Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol (2015) 0.91
Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res (2013) 0.91
Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor. Proc Natl Acad Sci U S A (2016) 0.89
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol (2015) 0.89
Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A. J Virol (2014) 0.89
Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology (2014) 0.89
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol (2016) 0.88
Hepcidin and the iron enigma in HCV infection. Virulence (2014) 0.88
Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol (2016) 0.88
XRN1 stalling in the 5' UTR of Hepatitis C virus and Bovine Viral Diarrhea virus is associated with dysregulated host mRNA stability. PLoS Pathog (2015) 0.88
New treatment strategies for hepatitis C infection. World J Hepatol (2015) 0.88
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Characterization of nonprimate hepacivirus and construction of a functional molecular clone. Proc Natl Acad Sci U S A (2015) 0.87
A method for near full-length amplification and sequencing for six hepatitis C virus genotypes. BMC Genomics (2016) 0.86
Innate immune cell networking in hepatitis C virus infection. J Leukoc Biol (2014) 0.86
Dissecting the roles of the 5' exoribonucleases Xrn1 and Xrn2 in restricting hepatitis C virus replication. J Virol (2015) 0.86
How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol (2014) 0.85
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother (2014) 0.85
Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site. Bioorg Med Chem Lett (2014) 0.85
Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol (2014) 0.84
Daclatasvir: potential role in hepatitis C. Drug Des Devel Ther (2013) 0.84
Virologic Tools for HCV Drug Resistance Testing. Viruses (2015) 0.83
Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle. J Virol (2015) 0.83
Pathophysiology of lipid droplet proteins in liver diseases. Exp Cell Res (2015) 0.83
Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. Curr HIV/AIDS Rep (2013) 0.83
T cell responses in hepatitis C virus infection: historical overview and goals for future research. Antiviral Res (2014) 0.82
Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol (2016) 0.81
Chronic hepatitis C virus infection and lipoprotein metabolism. World J Gastroenterol (2015) 0.81
Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition. Proc Natl Acad Sci U S A (2016) 0.80
A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs. Nat Commun (2016) 0.80
Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. Gene Ther (2014) 0.80
Studying the immune response to human viral infections using zebrafish. Dev Comp Immunol (2014) 0.80
TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus. PLoS One (2015) 0.80
Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094. Antimicrob Agents Chemother (2016) 0.79
HCV E2 core structures and mAbs: something is still missing. Drug Discov Today (2014) 0.79
Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol (2014) 0.79
New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr (2016) 0.79
Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. Trends Microbiol (2016) 0.79
Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B. Antimicrob Agents Chemother (2014) 0.79
Protein interactions during the flavivirus and hepacivirus life cycle. Mol Cell Proteomics (2017) 0.79
Phosphoproteomics Identified an NS5A Phosphorylation Site Involved in Hepatitis C Virus Replication. J Biol Chem (2015) 0.79
Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6. Virology (2014) 0.79
Establishment of chronic hepatitis C virus infection: translational evasion of oxidative defence. World J Gastroenterol (2014) 0.79
Hepatitis C Viral Infection in Children: Updated Review. Pediatr Gastroenterol Hepatol Nutr (2016) 0.79
Unraveling hepatitis C virus structure. Cell Res (2014) 0.78
Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol (2015) 0.78
Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war? World J Gastroenterol (2015) 0.78
Ankyrin Repeat Domain 1 is Up-regulated During Hepatitis C Virus Infection and Regulates Hepatitis C Virus Entry. Sci Rep (2016) 0.78
Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. World J Gastroenterol (2014) 0.78
Inhibition of Hepatitis C Virus in Mice by a Small Interfering RNA Targeting a Highly Conserved Sequence in Viral IRES Pseudoknot. PLoS One (2016) 0.78
A Proline-Tryptophan Turn in the Intrinsically Disordered Domain 2 of NS5A Protein Is Essential for Hepatitis C Virus RNA Replication. J Biol Chem (2015) 0.78
Phosphorylation of Serine 235 of the Hepatitis C Virus Non-Structural Protein NS5A by Multiple Kinases. PLoS One (2016) 0.78
Viral hepatitis in hemodialysis: An update. J Transl Int Med (2015) 0.78
Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response. Viruses (2016) 0.77
Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med (2015) 0.77
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. PLoS Comput Biol (2015) 0.77
FR171456 is a specific inhibitor of mammalian NSDHL and yeast Erg26p. Nat Commun (2015) 0.77
Epoxide based inhibitors of the hepatitis C virus non-structural 2 autoprotease. Antiviral Res (2015) 0.77
Identification and biochemical characterization of halisulfate 3 and suvanine as novel inhibitors of hepatitis C virus NS3 helicase from a marine sponge. Mar Drugs (2014) 0.77
Type I interferon rapidly restricts infectious hepatitis C virus particle genesis. Hepatology (2014) 0.77
Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol (2014) 0.77
Hepatitis C virus NS5A protein blocks epidermal growth factor receptor degradation via a proline motif- dependent interaction. J Gen Virol (2015) 0.77
Hepatitis C Genotype Prevalence in Monastir Region, Tunisia: Correlation between 5' Untranslated Region (5'UTR), Non-structural 5B (NS5B), and Core Sequences in HCV Subtyping. Curr Microbiol (2016) 0.76
Insights into antiviral innate immunity revealed by studying hepatitis C virus. Cytokine (2015) 0.76
Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders. Antimicrob Agents Chemother (2014) 0.76
Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol (2016) 0.76
Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection. J Gen Virol (2015) 0.76
Immune and non-immune responses to hepatitis C virus infection. World J Gastroenterol (2015) 0.76
The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection. J Virol (2015) 0.76
Natural killer cells in hepatitis C: Current progress. World J Gastroenterol (2016) 0.76
Comparative Analysis of Salivary Gland Proteomes of Two Glossina Species that Exhibit Differential Hytrosavirus Pathologies. Front Microbiol (2016) 0.76
Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer. BMC Gastroenterol (2016) 0.76
Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation. Bone Marrow Transplant (2016) 0.76
Autophagy in HCV infection: keeping fat and inflammation at bay. Biomed Res Int (2014) 0.76
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84
Efficient initiation of HCV RNA replication in cell culture. Science (2000) 15.12
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol (2007) 8.98
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med (1989) 8.10
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 7.53
Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A (2006) 6.87
Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol (2002) 6.69
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A (1997) 6.09
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A (1999) 6.05
Hepatitis C virus replication in mice with chimeric human livers. Nat Med (2001) 5.87
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol (2002) 4.55
Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol (1999) 4.37
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A (2007) 4.05
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature (2005) 3.83
Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A (2005) 3.83
Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog (2008) 3.81
Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog (2008) 3.77
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci U S A (2009) 3.49
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest (2012) 3.46
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A (2002) 3.43
Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A (2003) 3.38
Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J (2002) 3.33
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat Med (2010) 3.27
Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol (2007) 3.18
The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem (2004) 3.15
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly. J Biol Chem (2007) 3.11
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology (2009) 3.10
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe (2011) 3.05
Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol (2008) 2.98
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol (2000) 2.89
The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell (1996) 2.81
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A (2013) 2.79
Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology (2003) 2.76
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature (2006) 2.58
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology (2010) 2.53
Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol (2008) 2.52
Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol (2010) 2.51
Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol (2007) 2.45
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis (2012) 2.41
Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A (2012) 2.39
Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol (2009) 2.39
Assembly of infectious hepatitis C virus particles. Trends Microbiol (2010) 2.36
The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog (2010) 2.28
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol (2008) 2.22
Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22
Structural determinants that target the hepatitis C virus core protein to lipid droplets. J Biol Chem (2006) 2.18
Characterization of a canine homolog of hepatitis C virus. Proc Natl Acad Sci U S A (2011) 2.14
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology (2011) 2.13
Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A (2011) 2.06
Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem (2010) 2.05
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog (2012) 2.04
Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol (2009) 2.00
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol (2007) 1.95
Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism. Proc Natl Acad Sci U S A (2009) 1.94
Regulation of hepatic innate immunity by hepatitis C virus. Nat Med (2013) 1.93
Bats are a major natural reservoir for hepaciviruses and pegiviruses. Proc Natl Acad Sci U S A (2013) 1.93
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
A diverse range of gene products are effectors of the type I interferon antiviral response. Nature (2011) 12.86
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16
Unravelling hepatitis C virus replication from genome to function. Nature (2005) 5.25
HCV persistence and immune evasion in the absence of memory T cell help. Science (2003) 5.23
Molecular biology of flaviviruses. Adv Virus Res (2003) 4.39
Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol (2007) 4.28
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 4.15
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature (2005) 3.83
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol (2011) 3.44
Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature (2013) 3.39
Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol (2004) 3.39
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci U S A (2002) 3.21
Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol (2003) 3.19
The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem (2004) 3.15
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J Virol (2002) 3.07
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A (2004) 2.77
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol (2007) 2.65
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature (2006) 2.58
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection. J Virol (2002) 2.55
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog (2010) 2.48
Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol (2007) 2.45
Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A (2010) 2.44
euHCVdb: the European hepatitis C virus database. Nucleic Acids Res (2006) 2.41
MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature (2013) 2.40
Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology (2004) 2.37
A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol (2004) 2.36
Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol (2002) 2.31
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med (2009) 2.26
A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol (2003) 2.25
Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 2.20
Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol (2003) 2.20
Characterization of a canine homolog of hepatitis C virus. Proc Natl Acad Sci U S A (2011) 2.14
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology (2011) 2.13
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology (2011) 2.06
Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science (2012) 2.06
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A (2004) 2.04
Tracking and elucidating alphavirus-host protein interactions. J Biol Chem (2006) 2.01
An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J Virol (2004) 1.99
Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism. Proc Natl Acad Sci U S A (2009) 1.94
Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol (2003) 1.93
Hepatitis C virus entry. J Biol Chem (2007) 1.91
Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol (2002) 1.87
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A (2013) 1.85
PKR-dependent and -independent mechanisms are involved in translational shutoff during Sindbis virus infection. J Virol (2004) 1.81
Serology-enabled discovery of genetically diverse hepaciviruses in a new host. J Virol (2012) 1.80
Uncleaved NS2-3 is required for production of infectious bovine viral diarrhea virus. J Virol (2004) 1.79
Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology (2006) 1.75
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog (2009) 1.73
Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus. J Virol (2007) 1.73
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood (2007) 1.72
Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med (2005) 1.71
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut (2014) 1.70
The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol (2013) 1.69
A dynamic view of hepatitis C virus replication complexes. J Virol (2008) 1.66
Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest (2006) 1.66
Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U S A (2007) 1.64
Studying hepatitis C virus: making the best of a bad virus. J Virol (2007) 1.62
3' RNA elements in hepatitis C virus replication: kissing partners and long poly(U). J Virol (2007) 1.62
Identification of rodent homologs of hepatitis C virus and pegiviruses. MBio (2013) 1.61
Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol (2002) 1.61
Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat Rev Microbiol (2008) 1.60
Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proc Natl Acad Sci U S A (2012) 1.48
Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology (2005) 1.47
Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med (2005) 1.46
Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology (2011) 1.42
Host factors associated with the Sindbis virus RNA-dependent RNA polymerase: role for G3BP1 and G3BP2 in virus replication. J Virol (2010) 1.38
Hepatitis C virus RNA synthesis in a cell-free system isolated from replicon-containing hepatoma cells. J Virol (2003) 1.36
Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J Exp Med (2012) 1.36
Dual mechanisms of pestiviral superinfection exclusion at entry and RNA replication. J Virol (2005) 1.35